CU24121B1 - Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen - Google Patents

Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen

Info

Publication number
CU24121B1
CU24121B1 CUP2012000112A CU20120112A CU24121B1 CU 24121 B1 CU24121 B1 CU 24121B1 CU P2012000112 A CUP2012000112 A CU P2012000112A CU 20120112 A CU20120112 A CU 20120112A CU 24121 B1 CU24121 B1 CU 24121B1
Authority
CU
Cuba
Prior art keywords
vesicles
growth factor
epidermal growth
compositions containing
include epidermal
Prior art date
Application number
CUP2012000112A
Other languages
English (en)
Other versions
CU20120112A7 (es
Inventor
Milián Héctor Jesús Santana
Rull Leonor Ventosa
Díaz Eduardo Martínez
Acosta Jorge Amador Berlanga
Cabrera Ingrid Puig
Miró Jaume Veciana
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24121(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Ingeniería Genética Y Biotecnología, Consejo Superior Investigacion filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CUP2012000112A priority Critical patent/CU24121B1/es
Priority to UAA201501774A priority patent/UA113448C2/uk
Priority to ARP130102727A priority patent/AR091951A1/es
Priority to JP2015524635A priority patent/JP6251740B2/ja
Priority to MX2015001561A priority patent/MX360674B/es
Priority to HK15111950.8A priority patent/HK1210970B/xx
Priority to EP13759116.0A priority patent/EP2915541B1/en
Priority to PL13759116T priority patent/PL2915541T3/pl
Priority to ES13759116.0T priority patent/ES2613087T3/es
Priority to RU2015106683A priority patent/RU2649781C2/ru
Priority to KR1020157005385A priority patent/KR101752757B1/ko
Priority to PCT/CU2013/000004 priority patent/WO2014019555A1/es
Priority to SG11201500797SA priority patent/SG11201500797SA/en
Priority to MYPI2015700300A priority patent/MY196771A/en
Priority to HRP20170145TT priority patent/HRP20170145T1/hr
Priority to RS20170122A priority patent/RS55713B1/sr
Priority to CN201380048721.3A priority patent/CN104684575B/zh
Priority to PT137591160T priority patent/PT2915541T/pt
Priority to DK13759116.0T priority patent/DK2915541T3/en
Priority to US14/418,511 priority patent/US9717776B2/en
Priority to CA2880404A priority patent/CA2880404C/en
Priority to SI201330504A priority patent/SI2915541T1/sl
Priority to AU2013299036A priority patent/AU2013299036C1/en
Priority to HUE13759116A priority patent/HUE033286T2/en
Priority to BR112015002103-4A priority patent/BR112015002103B1/pt
Publication of CU20120112A7 publication Critical patent/CU20120112A7/es
Priority to CL2015000254A priority patent/CL2015000254A1/es
Priority to ZA2015/00763A priority patent/ZA201500763B/en
Publication of CU24121B1 publication Critical patent/CU24121B1/es
Priority to US15/664,548 priority patent/US11510965B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

La invención se refiere a vesículas que comprenden el Factor de Crecimiento Epidérmico (EGF), un surfactante catiónico, y colesterol o sus derivados. La invención también revela un procedimiento para su preparación, basado en la tecnología de fluidos comprimidos (FCs). Las vesículas de la invención tienen utilidad en la fabricación de medicamentos y productos cosméticos, y en la ingeniería tisular.
CUP2012000112A 2012-08-02 2012-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen CU24121B1 (es)

Priority Applications (28)

Application Number Priority Date Filing Date Title
CUP2012000112A CU24121B1 (es) 2012-08-02 2012-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
UAA201501774A UA113448C2 (xx) 2012-08-02 2013-02-08 Везикули, які містять епідермальний фактор росту і його композиції
ARP130102727A AR091951A1 (es) 2012-08-02 2013-08-01 Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen
BR112015002103-4A BR112015002103B1 (pt) 2012-08-02 2013-08-02 Vesícula, processo para a preparação de vesículas, composição farmacêutica, uso de uma vesícula, e, produto cosmético
HRP20170145TT HRP20170145T1 (hr) 2012-08-02 2013-08-02 Čestice koje sadrže epidermalni faktor rasta i supstancije koje sadrže isti
CN201380048721.3A CN104684575B (zh) 2012-08-02 2013-08-02 包含表皮生长因子的囊泡和含有所述囊泡的组合物
HK15111950.8A HK1210970B (en) 2012-08-02 2013-08-02 Vesicles which include epidermal growth factor and compositions that contain same
EP13759116.0A EP2915541B1 (en) 2012-08-02 2013-08-02 Vesicles which include epidermal growth factor and compositions that contain same
PL13759116T PL2915541T3 (pl) 2012-08-02 2013-08-02 Pęcherzyki zawierające nabłonkowy czynnik wzrostu i kompozycje je zawierające
ES13759116.0T ES2613087T3 (es) 2012-08-02 2013-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
RU2015106683A RU2649781C2 (ru) 2012-08-02 2013-08-02 Везикулы, содержащие эпидермальный фактор роста и его композиции
KR1020157005385A KR101752757B1 (ko) 2012-08-02 2013-08-02 상피 성장 인자를 포함하는 소포체 및 이를 포함하는 조성물
PCT/CU2013/000004 WO2014019555A1 (es) 2012-08-02 2013-08-02 Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen
SG11201500797SA SG11201500797SA (en) 2012-08-02 2013-08-02 Vesicles which include epidermal growth factor and compositions that contain same
MYPI2015700300A MY196771A (en) 2012-08-02 2013-08-02 Vesicles which include epidermal growth factor and compositions that contain same
JP2015524635A JP6251740B2 (ja) 2012-08-02 2013-08-02 上皮増殖因子を含む小胞及びその組成物
RS20170122A RS55713B1 (sr) 2012-08-02 2013-08-02 Vezikule koje obuhvataju epidermalni faktor rasta i supstance koje isti sadrže
MX2015001561A MX360674B (es) 2012-08-02 2013-08-02 Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen.
PT137591160T PT2915541T (pt) 2012-08-02 2013-08-02 Vesículas que incluem fator de crescimento epidérmico e composições que contêm o mesmo
DK13759116.0T DK2915541T3 (en) 2012-08-02 2013-08-02 VESICLES INCLUDING EPIDERMAL GROWTH FACTOR AND COMPOSITIONS CONTAINING SAME
US14/418,511 US9717776B2 (en) 2012-08-02 2013-08-02 Vesicles comprising epidermal growth factor and compositions thereof
CA2880404A CA2880404C (en) 2012-08-02 2013-08-02 Vesicles comprising epidermal growth factor and compositions thereof
SI201330504A SI2915541T1 (sl) 2012-08-02 2013-08-02 Vezikli, ki vključujejo epidermalni rastni faktor in sestave, ki le-tega vsebujejo
AU2013299036A AU2013299036C1 (en) 2012-08-02 2013-08-02 Vesicles which include epidermal growth factor and compositions that contain same
HUE13759116A HUE033286T2 (en) 2012-08-02 2013-08-02 Vesicles containing epidermal growth factor and preparations containing them
ZA2015/00763A ZA201500763B (en) 2012-08-02 2015-02-02 Vesicles which include epidermal growth factor and compositions that contain same
CL2015000254A CL2015000254A1 (es) 2012-08-02 2015-02-02 Vesículas que comprenden factor de crecimiento epidermico (egf); proceso de preparación; composición farmacéutica que las comprende; y uso para tratar heridas complejas .
US15/664,548 US11510965B2 (en) 2012-08-02 2017-07-31 Vesicles comprising epidermal growth factor and compositions thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2012000112A CU24121B1 (es) 2012-08-02 2012-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen

Publications (2)

Publication Number Publication Date
CU20120112A7 CU20120112A7 (es) 2014-03-26
CU24121B1 true CU24121B1 (es) 2015-08-27

Family

ID=49118249

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2012000112A CU24121B1 (es) 2012-08-02 2012-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen

Country Status (26)

Country Link
US (2) US9717776B2 (es)
EP (1) EP2915541B1 (es)
JP (1) JP6251740B2 (es)
KR (1) KR101752757B1 (es)
CN (1) CN104684575B (es)
AR (1) AR091951A1 (es)
AU (1) AU2013299036C1 (es)
BR (1) BR112015002103B1 (es)
CA (1) CA2880404C (es)
CL (1) CL2015000254A1 (es)
CU (1) CU24121B1 (es)
DK (1) DK2915541T3 (es)
ES (1) ES2613087T3 (es)
HR (1) HRP20170145T1 (es)
HU (1) HUE033286T2 (es)
MX (1) MX360674B (es)
MY (1) MY196771A (es)
PL (1) PL2915541T3 (es)
PT (1) PT2915541T (es)
RS (1) RS55713B1 (es)
RU (1) RU2649781C2 (es)
SG (1) SG11201500797SA (es)
SI (1) SI2915541T1 (es)
UA (1) UA113448C2 (es)
WO (1) WO2014019555A1 (es)
ZA (1) ZA201500763B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241565A4 (en) * 2014-12-30 2018-07-18 Celltrion, Inc. Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same
CA3017571A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
WO2017123022A1 (ko) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
WO2017147407A1 (en) 2016-02-25 2017-08-31 Board Of Regents, The University Of Texas System Compositions comprising composite nanocarriers and methods of making and uses thereof
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
TWI636794B (zh) * 2017-11-06 2018-10-01 吳治增 一種奈米複合材料及其應用
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3920946A4 (en) 2019-02-07 2022-11-09 Direct Biologics LLC METHOD FOR TREATING OSTEOARTHRITIS USING A COMBINATION OF EXOSOMES OF MESENCHYMATE STEM CELLS, SYNOVIAL MESENCHYMATE STEM CELLS AND SCAFFOLDS
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
WO2021206328A1 (ko) * 2020-04-10 2021-10-14 한국과학기술연구원 신규 재조합 엑소좀 및 그의 용도
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
EP4035658A1 (en) * 2021-01-27 2022-08-03 Consejo Superior de Investigaciones Científicas (CSIC) Liposomes and its use for enzyme delivery
CN113827622B (zh) * 2021-08-31 2023-11-07 南方医科大学 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0272123A (ja) * 1988-09-07 1990-03-12 Hitachi Chem Co Ltd ヒト上皮細胞成長因子の投与方法及びヒト上皮細胞成長因子含有疾病治療剤
US5064655A (en) * 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5618544A (en) 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US20020081324A1 (en) * 2002-01-22 2002-06-27 Twine Rebecca Wright Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood
WO2003090662A2 (en) * 2002-04-25 2003-11-06 Rapidheal, Inc. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
ES2265262B1 (es) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
WO2007065464A1 (en) 2005-12-09 2007-06-14 Stichting Katholieke Universiteit Epidermal growth factor (egf) derivatives with selectable selectivity for the erb receptor family
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
JP2009234945A (ja) * 2008-03-26 2009-10-15 Shalom:Kk ｈ−ＥＧＦ含有スフィンゴミエリンリポソームおよびこれを配合した化粧料及び医薬品
CN102091034A (zh) * 2009-12-15 2011-06-15 哈尔滨工业大学 基于胆固醇衍生物的有机-无机复合纳米囊泡的制备
KR101102834B1 (ko) * 2010-02-24 2012-01-05 충남대학교산학협력단 신규한 리포좀 제조 방법 및 장치
WO2011138687A2 (en) * 2010-05-06 2011-11-10 Regenics As Use of cellular extracts for skin rejuvenation

Also Published As

Publication number Publication date
MX360674B (es) 2018-11-13
EP2915541A1 (en) 2015-09-09
AU2013299036B2 (en) 2017-12-14
AU2013299036A1 (en) 2015-03-19
DK2915541T3 (en) 2017-02-13
HRP20170145T1 (hr) 2017-04-07
MX2015001561A (es) 2015-09-29
JP2015527337A (ja) 2015-09-17
PL2915541T3 (pl) 2017-06-30
SI2915541T1 (sl) 2017-05-31
RU2015106683A (ru) 2016-09-27
US11510965B2 (en) 2022-11-29
RU2649781C2 (ru) 2018-04-04
AU2013299036C1 (en) 2018-03-29
HK1210970A1 (en) 2016-05-13
UA113448C2 (xx) 2017-01-25
RS55713B1 (sr) 2017-07-31
US20150182590A1 (en) 2015-07-02
CA2880404C (en) 2018-02-13
SG11201500797SA (en) 2015-03-30
PT2915541T (pt) 2017-02-13
ES2613087T3 (es) 2017-05-22
MY196771A (en) 2023-05-03
HUE033286T2 (en) 2017-11-28
BR112015002103A2 (pt) 2019-08-20
KR20150041795A (ko) 2015-04-17
BR112015002103B1 (pt) 2022-11-29
CA2880404A1 (en) 2014-02-06
CU20120112A7 (es) 2014-03-26
JP6251740B2 (ja) 2017-12-20
CN104684575A (zh) 2015-06-03
ZA201500763B (en) 2016-01-27
US9717776B2 (en) 2017-08-01
AR091951A1 (es) 2015-03-11
KR101752757B1 (ko) 2017-07-04
US20180015145A1 (en) 2018-01-18
EP2915541B1 (en) 2016-11-09
CN104684575B (zh) 2018-07-31
WO2014019555A1 (es) 2014-02-06
CL2015000254A1 (es) 2015-10-16

Similar Documents

Publication Publication Date Title
CU20120112A7 (es) Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR102013022698B8 (pt) Éster de poliglicerol, processo para a produção do mesmo, seu uso e formulação cosmética ou farmacêutica
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
BR112014017241A2 (pt) processo para a preparação de um poliéter-éster poliol, poliéter-éster poliol, e, uso de um poliéter-éster poliol
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
NZ702472A (en) Oil/water-emulsion-type topical compositions containing a retinoid
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
BR112013004839A2 (pt) anfifílico de fórmula (i), processos para preprarar o anfifílico de fórmula (i) e para a produção da composição, composição, utilização do anfifílico e material de propagação das plantas
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
MX2014014517A (es) Composiciones topicas bajo la forma de un gel que contiene un retinoide particular solubilizado.
BR112018008588A2 (pt) composição, e, processo para preparar uma composição.
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
MY164822A (en) Pharmaceutical compositions of carotenoid
MX2012007599A (es) Composiciones para formar peliculas que tienen un grado deseado de cobertura y metodos para hacer y usar las mismas.
MA34933B1 (fr) Preparation de nouveaux bio-composites chitosan-argile modifiee
MX2012014071A (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
BR112014027388A2 (pt) formulação de vitamina aquosa estéril

Legal Events

Date Code Title Description
FG Grant of patent